Event Title

GH6 -- Deep Vein Thrombosis (DVT) in Patients Diagnosed with COVID-19

Location

URC Greatroom

Start Date

8-4-2022 10:30 AM

End Date

8-4-2022 12:15 PM

Description

The COVID-19 virus has been a source of difficulty for healthcare providers due to its novel and ever-changing clinical characteristics. The literature indicates that the most common complications associated with COVID-19 morbidity and mortality are pulmonary emboli, pneumonia, and multi-organ failure. However, the question remains of the role of deep vein thromboses (DVTs) in contributing to negative outcomes in COVID-19 patients. Recent studies have discovered findings suggestive of a unique COVID-19 induced hypercoagulable state through a range of mechanisms, including an exaggerated neutrophil response and direct viral induction of thrombotic cytokines. The goal of this study is to determine the effect of DVTs in COVID-19 patients. A retrospective evaluation of DVT identification and incidence in COVID-19 patients at a single institution between 6/30/2020 and 12/31/2021 will be completed. Typical demographic and clinicopathologic data will be collected to include, but not limited to, comorbidities (heart disease, previous thrombotic events, and chronic steroid use), radiologic findings associated with pulmonary emboli (PE) and DVT (concurrent presentation, locations), treatments and outcomes. Data will be analyzed using Fisher’s t-test and ANOVA where appropriate. Data will be compared to published studies, especially those suggesting that COVID-19 pulmonary emboli occur in anatomically unique places in the pulmonary vasculature compared to hematogenous spreading PEs from DVTs. Initial findings noted that the majority of COVID-19 induced DVTs occurred within the first 4 days of the diagnosis, suggesting immediate and intense anticoagulation therapy early in COVID-19 hospital courses could minimize thrombotic complications and maximize positive outcomes for patients.

This document is currently not available here.

Share

COinS
 
Apr 8th, 10:30 AM Apr 8th, 12:15 PM

GH6 -- Deep Vein Thrombosis (DVT) in Patients Diagnosed with COVID-19

URC Greatroom

The COVID-19 virus has been a source of difficulty for healthcare providers due to its novel and ever-changing clinical characteristics. The literature indicates that the most common complications associated with COVID-19 morbidity and mortality are pulmonary emboli, pneumonia, and multi-organ failure. However, the question remains of the role of deep vein thromboses (DVTs) in contributing to negative outcomes in COVID-19 patients. Recent studies have discovered findings suggestive of a unique COVID-19 induced hypercoagulable state through a range of mechanisms, including an exaggerated neutrophil response and direct viral induction of thrombotic cytokines. The goal of this study is to determine the effect of DVTs in COVID-19 patients. A retrospective evaluation of DVT identification and incidence in COVID-19 patients at a single institution between 6/30/2020 and 12/31/2021 will be completed. Typical demographic and clinicopathologic data will be collected to include, but not limited to, comorbidities (heart disease, previous thrombotic events, and chronic steroid use), radiologic findings associated with pulmonary emboli (PE) and DVT (concurrent presentation, locations), treatments and outcomes. Data will be analyzed using Fisher’s t-test and ANOVA where appropriate. Data will be compared to published studies, especially those suggesting that COVID-19 pulmonary emboli occur in anatomically unique places in the pulmonary vasculature compared to hematogenous spreading PEs from DVTs. Initial findings noted that the majority of COVID-19 induced DVTs occurred within the first 4 days of the diagnosis, suggesting immediate and intense anticoagulation therapy early in COVID-19 hospital courses could minimize thrombotic complications and maximize positive outcomes for patients.